HomeMCPWorkbenchSkills
HomeWorkbenchNotificationsMe
llms.txt · MCP GuidePrivacy Policy · Terms of Service · Supportv1.8.3
  1. Home
  2. /Compound

Bepotastine

HCID 164522
New reaction
Print
Basic informationOverviewNames & identifiersPropertiesSafety & regulationChemistry & industryRelated reactionsCompound notes
Substructure searchFind similar structures

Basic information

CAS
125602-71-3
Standard SMILES
O=C(O)CCCN1CCC(O[C@@H](c2ccc(Cl)cc2)c2ccccn2)CC1
InChIKey
YWGDOWXRIALTES-NRFANRHFSA-N
Molecular formula
C21H25ClN2O3
Average molar mass
388.9 g/mol
Monoisotopic mass
388.15537034

Overview

Bepotastine is an ether that is (S)-(4-chlorophenyl)(pyridin-2-yl)methanol in which the hydroxyl hydrogen is substituted by a 1-(3-carboxypropyl)piperidin-4-yl group. A topical, selective and non-sedating histamine (H1) receptor antagonist used (as its benzenesulfonate salt) for treatment of itching associated with allergic conjunctivitis. It has a role as a H1-receptor antagonist and an anti-allergic agent. It is a monocarboxylic acid, an ether, a member of piperidines, a member of pyridines and a member of monochlorobenzenes. It is a conjugate base of a bepotastine(1+).

Names & identifiers

Preferred name
Bepotastine
IUPAC
4-[4-[(S)-(4-chlorophenyl)-pyridin-2-ylmethoxy]piperidin-1-yl]butanoic acid
English name
BEPOTASTINE
Molecular formula
C21H25ClN2O3
Molecular weight
388.89

Names & synonyms

Bepotastine125602-71-3BetotastinebepotastinaTau 284bepotastinum4-[4-[(S)-(4-chlorophenyl)-pyridin-2-ylmethoxy]piperidin-1-yl]butanoic acidHYD2U48IASCHEBI:71204DTXSID90904947(S)-4-(4-((4-Chlorophenyl)(2-pyridil)methoxy)piperidino)butylic acid(+)-4-(((S)-p-Chloro-alpha-2-pyridylbenzyl)oxy)-1-piperidinebutyric acid
Show more names
Bestatin (i.eBepotastine >(S)-BepotastineBepotastine >90%betotastine besilateBepotastine free baseBepotastine (Standard)-4-(4-((4-Chlorophenyl)Bepotastine, 10 mM in DMSO
TAU-2841-Piperidinebutanoic acid, 4-((4-chlorophenyl)-2-pyridinylmethoxy)-4-(4-((S)-(4-chlorophenyl)-pyridin-2-ylmethoxy)piperidin-1-yl)butanoic acidRefChem:56382DTXCID201334062(S)-4-(4-((4-chlorophenyl)(2-pyridil)methoxy)piperidino)butylic acid monobenzenesulfonate4-(4-((4-chlorophenyl)(pyridin-2-yl)methoxy)piperidin-1-yl)butanoic acid(S)-4-(4-((4-Chlorophenyl)(pyridin-2-yl)methoxy)piperidin-1-yl)butanoic acid

Properties

Computed structural properties

XLogP
1
Topological polar surface area
62.7 Ų
Hydrogen bond donors
1
Hydrogen bond acceptors
5
Rotatable bonds
8
Heavy atoms
27
Formal charge
0
Complexity
449

Experimental & physicochemical properties

DrugsPharmaceuticals -> Listed in ZINC15
Human DrugsBreast Feeding; Lactation; Milk, Human; Anti-Allergic Agents; Antihistamines

Physicochemical properties

Melting point
56 · 56 - 58°C
Boiling point
546.8 · 546.8±50.0 °C(Predicted)
Density
1.26 · 1.26
storage temp.
-20 °C · -20°C Freezer, Under inert atmosphere
solubility
DMSO (Slightly), Methanol (Slightly)
pka
4.44 · 4.44±0.10(Predicted)
form
Solid
color
White to Pale Beige
InChIKey
YWGDOWXRIALTES-NRFANRHFSA-N
SMILES
[C@@H](C1N=CC=CC=1)(C1C=CC(=CC=1)Cl)OC1CCN(CC1)CCCC(=O)O
FDA UNII
2 U48IAS · HYD2U48IAS

Safety & regulation

Safety information is for reference only and does not replace the supplier’s Safety Data Sheet (SDS), applicable regulations, or professional assessment.

Toxicology

Exposure Routes · 1 item

Oral, Ophthalmic. Tmax, after single dose, opthalmic = 1.2 hours; Cmax, 1.5%, opthalmic dose = 7.3 ± 1.9 ng/mL; After 24 hours post-installation, levels of bepotastine are below quantifiable limit of 2 ng/mL. Minimal systemic absorption with opthalmic dosage form.

Toxicity Summary · 1 item

Because of a type 1 hypersensitivity reaction cascade that is triggered by antigen exposure, allergic conjunctivitis occurs. Allergen exposure is followed by conjunctival mast cell degranulation and histamine released as a result of the formation of complementary IgE cross-links on the conjunctiva. Due to the release of histamine, symptoms such as itching can be observed. Bepotastine works to relieve itchy eyes by three primary mechanisms of action. It is a non-sedating, selective antagonist of the histamine 1 (H1) receptor, a mast cell stabilizer, and it suppresses the migration of eosinophils into inflamed tissues to prevent tissue damage and worsening of allergic inflammation of the conjunctiva.

Carcinogen ClassificationNo indication of carcinogenicity to humans (not listed by IARC).
Effects During Pregnancy and Lactation◉ Summary of Use during Lactation

Chemistry & industry

Pharmacology

Protein Binding55.4% mean plasma protein binding with 10 mg oral dose. Extent of protein binding is independent of plasma drug concentration.
Pharmacodynamics · 1 item

Bepotastine is a non-sedating, selective antagonist of the histamine 1 (H1) receptor. It belongs to the second-generation piperidine chemical class. It is a mast cell stabilizer and suppresses the migration of eosinophils into inflamed tissues. Furthermore, bepotastine does not interact with serotonin, muscarinic, benzodiazepine, and beta-adrenergic receptor that would otherwise result in adverse reactions such as dry mouth or sonmolence. Onset of action = 0.25 hours; Duration of action = 12-24 hours;

Mechanism of Action · 1 item

Because of a type 1 hypersensitivity reaction cascade that is triggered by antigen exposure, allergic conjunctivitis occurs. Allergen exposure is followed by conjunctival mast cell degranulation and histamine released as a result of the formation of complementary IgE cross-links on the conjunctiva. Due to the release of histamine, symptoms such as itching can be observed. Bepotastine works to relieve itchy eyes by three primary mechanisms of action. It is a non-sedating, selective antagonist of the histamine 1 (H1) receptor, a mast cell stabilizer, and it suppresses the migration of eosinophils into inflamed tissues to prevent tissue damage and worsening of allergic inflammation of the conjunctiva.

Biological Half-LifeElimination half life = 2.5 hours
Metabolism/Metabolites · 2 items

Minimal metabolism via CYP enzymes

Minimal metabolism via CYP enzymes Route of Elimination: When a oral dose of 2.5 - 40 mg bepotastine is given, 75%-90% of the dose was excreted unchanged in the urine by 24 hours. Half Life: Elimination half life = 2.5 hours

FDA Pharmacological Classification · 4 items

HYD2U48IAS

BEPOTASTINE

Established Pharmacologic Class [EPC] - Histamine-1 Receptor Antagonist

Bepotastine is a Histamine-1 Receptor Antagonist.

Related reactions

9 records
New reaction record
HRID 381668 reaction equation
HRID 381668As product
HRID 381669 reaction equation
HRID 381669As reactant
HRID 381670 reaction equation
HRID 381670As reactant
HRID 1180647 reaction equation
HRID 1180647As product
HRID 1180648 reaction equation
HRID 1180648As reactant
HRID 1180649 reaction equation
HRID 1180649As reactant
HRID 1837026 reaction equation
HRID 1837026As product
HRID 1837027 reaction equation
HRID 1837027As reactant
PreviousPage 1 of 2

Compound notes

On this pageBasic informationOverviewNames & identifiersPropertiesSafety & regulationChemistry & industryRelated reactionsCompound notes

Database identifiers

CAS
125602-71-3
PubChem CID
164522
DTXSID
DTXSID90904947
ChEMBL
CHEMBL1201758
ChEBI
CHEBI:71204
UNII
HYD2U48IAS
Nikkaji
J824.035C
Absorption, Distribution and Excretion · 2 items

Tmax, after single dose, opthalmic = 1.2 hours; Cmax, 1.5%, opthalmic dose = 7.3 ±1.9 ng/mL; After 24 hours post-installation, levels of bepotastine are below quantifiable limit of 2 ng/mL. Minimal systemic absorption with opthalmic dosage form.

When a oral dose of 2.5 - 40 mg bepotastine is given, 75%-90% of the dose was excreted unchanged in the urine by 24 hours.

Uses & manufacturing

UsesFor the symptomatic treatment of itchy eyes (caused by IgE-induced mast cell degranulation) due to allergic conjunctivitis. Used in the treatment of allergic rhinitis and uriticaria/puritus. [Wikipedia]
Applications · 1 item

UsesBepotastine is a histamine H1 receptor antagonist. Bepotastine suppresses some allergic inflammatory processes such as allergic rhinitis, chronic urticaria or pruritus associated with skin conditions (eczema/dermatitis, prurigo or pruritus cutaneus).

Additional notes · 1 item

DefinitionChEBI: An ether that is (S)-(4-chlorophenyl)(pyridin-2-yl)methanol in which the hydroxyl hydrogen is substituted by a 1-(3-carboxypropyl)piperidin-4-yl group. A topical, selective and non-sedating histamine (H1) receptor anta onist used (as its benzenesulfonate salt) for treatment of itching associated with allergic conjunctivitis.